Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 16Other hematologic neoplasm 13Plasma cell 8Thoracic 7Gynecologic 3Gastrointestinal 3Dermatologic 2Tumor-Agnostic 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Recurrence 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 623Radiotherapy 410Bevacizumab 256Magnetic Resonance Spectroscopy 226Cyclophosphamide 179Radiosurgery 162Carboplatin 160Etoposide 132Radiation 128Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 83Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Maintenance × CNS × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡